Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ASCO 2019 | Immunotherapy priming with neo-antigens

Thomas Helleday • 1 Jun 2019
ASCO 2019
Gynecological Cancer Ovarian Cancer

Here, Thomas Helleday, PhD, from the University of Sheffield, Sheffield, UK, discusses the use of neo-antigens to prime tumors for immunotherapy treatment. This interview was recorded at the American Society of Oncology (ASCO) 2019 Annual Meeting, held in Chicago, IL.

More from Thomas Helleday

2:40
Targeting the DNA damage response
Thomas Helleday • 29 Sep 2019
1:47
Challenges in treating cancers of unknown primary (CUP)
Thomas Helleday • 29 Sep 2019
1:25
PARP inhibitors for ovarian cancer - room for improvement with HRD testing
Thomas Helleday • 30 Sep 2019
3:07
The DNA damaging revolution
Thomas Helleday • 1 Jun 2019

Related Videos

0:39
Early diagnosis of ovarian cancer with Pap smears
Sergio Marchini • 8 Apr 2024
0:46
FRa expression and sequencing ADCs in endometrial cancer
Rebecca Porter • 8 Apr 2024
4:12
PETRA: saruparib in solid tumors with BRCA1/2, PALB2 or RAD51C/D mutations
Timothy Yap • 7 Apr 2024
1:11
Clonal hematopoiesis mutations in ovarian carcinomas
Rebecca Porter • 8 Apr 2024
The content of VJOncology is intended for healthcare professionals